Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2018 | Updates on biomarkers for therapy in lung cancer

Keith Kerr • 22 Oct 2018
ESMO 2018
Lung Cancer

Beyond PD-L1 expression, there have been developments in biomarkers for therapy in lung cancer. Keith Kerr, MBChB, FRCPath, FRCPE, of Aberdeen University Medical School, Aberdeen, UK, discusses these updates, covering ROS1, RET, NTRK and MET, from the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany. Prof. Kerr also comments on the need to improve immuno-oncology biomarker testing beyond PD-L1.

More from Keith Kerr

2:55
Challenges of biomarker testing in the UK
Keith Kerr • 26 Apr 2023
3:32
Biomarker testing for ADCs
Keith Kerr • 27 Apr 2023
2:16
Pathology training in the molecular era
Keith Kerr • 24 Jan 2019
2:14
Pathology practice, an ever-changing field as more biomarkers emerge
Keith Kerr • 24 Jan 2019

Related Videos

2:03
Biomarker detection for early cancer detection
Robert Rintoul • 19 Apr 2024
0:45
Assessing treatment options for lung cancer with interstitial lung disease
Matthew Hatton • 18 Apr 2024
2:26
Targeting KRAS mutations in lung cancer
Thomas Newsom-Davis • 18 Apr 2024
1:47
Assessing follow-up strategies in post-surgical lung cancer: insights from a Phase III trial
Robert Rintoul • 19 Apr 2024
The content of VJOncology is intended for healthcare professionals